
Council for Innovation Promotion
3.8K posts

Council for Innovation Promotion
@Council4IP
C4IP is a bipartisan coalition dedicated to promoting strong and effective IP rights that drive innovation, boost economic competitiveness, and improve lives.














Yesterday, our chief legal and intellectual property officer, Karin Hessler, joined key industry and legal experts - Robert Cerwinski, Ryan Daniel, Charles Duan, Kevin Zive and Joseph Matal - for a stakeholder briefing on 'The Effect of @uspto Policy on Competition and Drug Prices.' The panel provided timely insights into how the PTAB’s proposed rulemaking limiting access to inter partes review (IPR) impacts market competition, generic and biosimilar medicines entry, drug pricing--and ultimately, America's patients. During the briefing, Ryan Daniel cited two specific examples to help illustrate how filing IPRs helps bring lower-cost medicines to patients years sooner than without the IPR strategy. And Kevin Zive summed up what happens if generic and biosimilar companies stop challenging patents on brand drugs, very clearly sharing that if these challenges stop, the amount people pay for medications will stay higher, for longer. And it was Karin Hessler who offered a specific call to action for Congress, around the urgency of preserving the IPR system, "We have serious concerns as the generic and biosimilar medicines industry [on the PTAB’s proposed rulemaking]. You give up defenses that can’t even be raised in an IPR. It just doesn’t mechanically work… We want everyone in Congress to better understand how important IPRs are to affordable drug prices.” Thanks again to our panelists and a very engaged group of nearly 70 attendees. We appreciate everyone's dedication to America's patients and attention on this important issue that could harshly and negatively impact the accessibility of affordable prescription treatment options in the United States. @BiosimsCouncil







